Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders

References

• Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr. Bull.19, 609–618 (1993).
   PubMed Web of Science ®Google Scholar
• Awad AG. Behavioural and subjective side effects. In: Managing The Side Effects Of Drug Therapy In Schizophrenia. Kane J (Ed.). Science Press, London, UK 1–14 (1999).
   Google Scholar
• Awad AG, Voruganti L, Heslegrave RJ, Hogan TP. Assessment of the patient’s subjective experiences in acute neuroleptic treatment: implications for compliance and outcome. Int. Clin. Psychopharmacol.11(Suppl. 2), 55–59 (1996).
   PubMedGoogle Scholar
• Hogan TP, Awad AG, Eastwood MR. Early subjective response and prediction of outcome to neuroleptic drug therapy. Can. J. Psychiatry30, 246–248 (1985).
   PubMed Web of Science ®Google Scholar
• Van Putten T, Marder SR. Behavioural toxicity of antipsychotic drugs. J. Clin. Psychiatry48, 13–19 (1987).
   PubMed Web of Science ®Google Scholar
• Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology171, 121–132 (2004).
   PubMed Web of Science ®Google Scholar
• Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptic in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry9, 585–588 (1985).
   PubMed Web of Science ®Google Scholar
• Awad AG. Drug therapy in schizophrenia – variability of outcome and prediction of response. Can. J. Psychiatry34, 711–720 (1989).
   PubMed Web of Science ®Google Scholar
• Hogan TP, Awad AG. Subjective response to neuroleptic and outcome in schizophrenia – a re-examination of two measures. Psychol. Med.22, 347–352 (1992).
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Rapkin B, Mott T et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr. Bull.20, 297–310 (1994).
   PubMed Web of Science ®Google Scholar
• Naber DA. Self-rating scale to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life and other clinical variables. Int. J. Clin. Psychopharmacol.10(Suppl. 3), 123–133 (1995).
   Google Scholar
• Voruganti L, Awad AG. Personal evaluation of transition in treatment (PETiT): a scale to measure subjective tolerability of antipsychotic medications. Schizophr. Res.56, 37–46 (2002).
   PubMed Web of Science ®Google Scholar
• Davidhizar RE. Can clients with schizophrenia describe feelings and beliefs about medications? J. Adv. Neurol.10, 469–473 (1985).
   Google Scholar
• Voruganti L, Heselgrave RJ, Awad AG. Seeman M. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol. Med.28, 165–172 (1998).
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti L. The subjective/objective dichotomy; implications for nosology, treatment and research. In: Zukunftsperspek Tiven in Psychiatrie und Psychoterapie-Steinkopff Verlay. Gaebel W (Ed.). Darmstadt, Germany 21–27 (2000).
   Google Scholar
• Liraud R, Droulout T, Parrot M, Verdoux H. Agreement between self-rated and clinically assessed symptoms in subjects with psychosis. J. Nerv. Ment. Dis.192, 352–356 (2004).
   PubMed Web of Science ®Google Scholar
• Naber D, Walther A, Kircher T, Hayek D, Holzbach R. Subjective effects of neuroleptics predict compliance. In: Prediction of Neuroleptic Treatment Outcome in Schizophrenia Concepts and Methods. Gaebel W, Awad AG (Eds). Springer-Verlag, NY, USA 85–98 (1994).
   Google Scholar
• Brounie S, Grevan J, Gervin M, Rae M, Larkin C, O’Callaghan E. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J. Nerv. Ment. Dis.186, 74–78 (1998).
   PubMed Web of Science ®Google Scholar
• Bartko G, Herczeg I, Bekesy M. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J. Clin. Psychiatry48, 363–365 (1987).
   PubMed Web of Science ®Google Scholar
• Cabeza IG, Amador MS, Lopez CA, Chavex MG. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr. Res.41, 349–355 (2000).
   PubMed Web of Science ®Google Scholar
• Swerdlow NR, Koob GF. Dopamine, schizophrenia, manic and depression: towards a unified hypothesis of cortico–striatal–pallido–thalamic function. Behav. Brain Sci.10, 197–245 (1987).
   Web of Science ®Google Scholar
• Caine ED, Polinsky RJ. Haloperidol-induced dysphoria in patients with Tourette syndrome. Am. J. Psychiatry136, 1216–1217 (1979).
   PubMed Web of Science ®Google Scholar
• Friedenberg DL, Cummings JL. Parkinson’s disease, depression and the on–off phenomenon. Psychosomatics30, 94–99 (1989).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction and in humans. J. Psychopharmacol.13, 337–345 (1999).
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, van Dyck CH et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med.36, 1182–1190 (1995).
   PubMed Web of Science ®Google Scholar
• Voruganti L, Slomka P, Zabel P et al. Subjective effects of AMPT induced dopamine depletion in schizophrenia: the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology25, 642–650 (2001).
   PubMed Web of Science ®Google Scholar
• Voruganti L, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia – findings from an in vivo SPECT study. Schizophr. Res.88, 179–186 (2006).
   PubMed Web of Science ®Google Scholar
• Seeman P, Ulpian C, Bergeron C et al. Bimodal distribution of dopamine receptor densities in brains of schizophrenic. Science225, 728–731 (1984).
   PubMed Web of Science ®Google Scholar
• Hietala J, Syralahti E, Vilkman H et al. Depressive symptoms and pre-synaptic dopamine function in neuroleptic naïve schizophrenia. Schizophr. Res.35, 41–50 (1999).
   PubMed Web of Science ®Google Scholar
• deHaan L, Lavalaye J, Linszen D, Dingemans PMAJ, Booij J. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am. J. Psychiatry157, 1019–1020 (2000).
   PubMed Web of Science ®Google Scholar
• Mueser KT, Yarnold PR, Levinson DF. Prevalence of substance abuse in schizophrenia. Demographics and clinical correlates. Schizophr. Bull.16, 31–54 (1990).
   PubMed Web of Science ®Google Scholar
• Reigier DA, Farner ME, Rae DS. Comorbidity of mental disorder with alcohol and other drugs of abuse. JAMA264, 2511–2518 (1990).
   PubMed Web of Science ®Google Scholar
• Khantzian E. The self-medication hypothesis of addictive disorders. Am. J. Psychiatry142, 1259–1264 (1985).
   PubMed Web of Science ®Google Scholar
• Voruganti LNP, Heselgrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J. Nerv. Ment. Dis.186, 74–78 (1998).
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LNP. Neuroleptic dysphoria, comorbid drug abuse in schizophrenia and the emerging science of subjective tolerability – towards a new synthesis. J. Dual Diagnosis1, 83–93 (2005).
   Google Scholar
• Smith MJ, Barch DM, Wof TJ, Mamah D, Csernansky JG. Elevated rates of substance disorders in non-psychotic siblings of individuals with schizophrenia. Schizophr. Res.106, 294–299 (2008).
   PubMed Web of Science ®Google Scholar
• Chambers AR, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry50, 71–83 (2001).
   PubMed Web of Science ®Google Scholar
• Koob GF, Moal M. Drug abuse: hedonic homeostatic disregulation. Science278, 52–58 (1997).
   PubMed Web of Science ®Google Scholar
• Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of stress. Am. J. Psychiatry126, 1483–1493 (2005).
   Google Scholar
• Kosteu TA, Nestler EJ. Clozapine attenuates cocaine conditioned place preference. Life Sci.55, PL9–PL14 (1994).
   PubMed Web of Science ®Google Scholar
• Noordsy DL, Green AL. Pharmacotherapy for schizophrenia and co-occurring substance use disorder. Curr. Psychiatry Rep.5, 340–346 (2003).
   PubMedGoogle Scholar